AusperBio Announces Completion of Patient Enrollment in Two Phase II Clinical Trials for AHB-137, an Investigational ASO Therapy for Chronic Hepatitis B

AB-10-8007 (NCT07069569) is a randomized, open-label, multi-center Phase II clinical study. The company has received the "Drug Clinical Trial Approval Notice" issued by the CDE, approving the company to conduct a study aimed at evaluating the efficacy and safety of AHB-137 injection in combination with hepatitis B vaccine or pegylated interferon α-2b (Peg-IFN) in HBeAg-negative chronic hepatitis B (CHB) subjects who are currently undergoing nucleos(t)ide analog (NA) treatment.

AB-10-8008 (NCT06829329) is a randomized, multi-center Phase II clinical study aimed at evaluating the efficacy and safety of AHB-137 injection in treatment-naïve patients with chronic hepatitis B (CHB). This study aims to explore the expansion of the AHB-137 treatment regimen to a broader patient population.

AboutAHB-137

AHB-137 is a non-conjugated antisense oligonucleotide (ASO) with the potential to become a cornerstone therapy for the clinical cure of chronic hepatitis B. As the first innovative drug from AusperBio's self-developed Med-Oligo™ platform to enter clinical trials, AHB-137 has demonstrated excellent data in preclinical studies and at several international authoritative academic conferences (including EASL™ 2023–2025, AASLD™ 2024, and APASL™ 2025), garnering widespread attention. Currently, AHB-137 is undergoing Phase III clinical trials in mainland China, Phase II clinical trials for combination therapy and treatment-naïve patients, while simultaneously advancing Phase II clinical trials overseas, accelerating the goal of achieving a clinical cure for hepatitis B through global strategic planning.

AboutAusperBio

AusperBio, a clinical-stage innovative drug development company operating simultaneously in China and the United States, focuses on developing proprietary targeted delivery small nucleic acid drugs with First-in-class and Best-in-class potential. The company owns the fully independent intellectual property rights of the Med-Oligo™ ASO technology platform, primarily concentrating on functional cures for chronic hepatitis B (HBV) and highly efficient targeted treatments for liver diseases, while actively expanding into new target areas beyond the liver. AusperBio's strategy is to combine its globally leading Med-Oligo™ oligonucleotide technology with specific and efficient targeted delivery platforms to advance the development of a series of innovative therapies, addressing significant unmet medical needs.

Source:

1.AusperBio